Evidence map›Paper›PMID 40764493›Full record

ArticleNPJ vaccines2025

Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization.

Behdad Zarnegar, Berit Carow, Jens Eriksson, Eva Spennare, Pontus Öhlund, Eray Akpinar, Emelie Bringeland, Ingrid Lekberg Osterman, Lena Lundqvist, Johanna Antti and 8 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Behdad Zarnegar *Novavax AB, Uppsala, Sweden.
Berit Carow *Novavax AB, Uppsala, Sweden. bcarow@novavax.com.
Jens ErikssonDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Eva SpennareNovavax AB, Uppsala, Sweden.
Pontus ÖhlundNovavax AB, Uppsala, Sweden.
Eray AkpinarNovavax AB, Uppsala, Sweden.
Emelie BringelandNovavax AB, Uppsala, Sweden.
Ingrid Lekberg OstermanNovavax AB, Uppsala, Sweden.
Lena LundqvistNovavax AB, Uppsala, Sweden.
Johanna AnttiNovavax AB, Uppsala, Sweden.
Niklas HandinNovavax AB, Uppsala, Sweden.
Per-Henrik HelgessonNovavax AB, Uppsala, Sweden.
Johan BankeforsNovavax AB, Uppsala, Sweden.
Karin Lövgren BengtssonNovavax AB, Uppsala, Sweden.
Mikael E SellinDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Anna-Karin E PalmNovavax AB, Uppsala, Sweden.
Linda StertmanNovavax AB, Uppsala, Sweden.
Carolina Lunderius AnderssonNovavax AB, Uppsala, Sweden.

Funding

Novavax AB N/A
6 · The paper itself

Abstract

Matrix-M

Identifiers

PMID40764493
PMCPMC12325594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.